Actos® Injury Lawyers
Actos® (pioglitazone) is a medication manufactured by Takeda Pharmaceuticals which is prescribed to control glucose (blood sugar) in adults with Type 2 diabetes. It is sold under the brand name Actos, as well as ACTOplus Met®, Duetact®, and the generic name, Pioglitazone.
In June 2011, the Food and Drug Administration (FDA) issued a Safety Announcement regarding Actos and related medications due to the risk of bladder cancer associated with using these medications. The FDA’s Announcement was based on their review of data from a planned five-year interim analysis of an ongoing ten year study. Preliminary results from the study showed a 40 percent increase in the risk for bladder cancer in patients taking Actos for more than one year. To see the FDA announcement, click here.
An increased risk of bladder cancer was observed among patients with the longest exposure to Actos, as well as in those exposed to the highest cumulative dose of Actos." 1
As a result of these findings, the FDA advised Actos users that there may be an increased likelihood of developing bladder cancer in connection with use of Actos/pioglitazone. The FDA has advised Actos users to tell their doctor right away if they have any of the following symptoms of bladder cancer:
- Blood in the urine
- Discolored urine
- An urgent need to urinate
- Painful urination
- Frequent urination
- Pain in the lower back or abdomen
- Weight loss
Thousands of lawsuits across the nation have been filed against Takeda on behalf of individuals diagnosed with bladder cancer after ingesting Actos. These lawsuits allege that the drug maker failed to adequately warn patients about the potential risk of bladder cancer associated with Actos use. In April 2015, Takeda agreed to pay $2.4 billion to settle all bladder cancer claims brought against the company.
In light of these settlements, Schlichter Bogard & Denton is no longer accepting Actos cases and therefore the information on this page is provided for informational purposes.
1 - Source: U.S. Food and Drug Administration